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IS THE VAGUS NERVE STIMULATION A WAY 
TO DECREASE BODY WEIGHT IN HUMANS?
Abstract: Is the vagus nerve stimulation a way to decrease body weight in humans?
Obesity and its complications constitute an important health problem in growing number of people. 
Behavioral and pharmacological treatment is not much effective and surgical treatment carries too 
many threats. Promising method to be used is pharmacological or electric manipulation of vagus 
nerves. 
Regulation of food intake and energy utilization is a complex process regulated by centers in 
hypothalamus and brainstem which are receiving information from the peripheral via afferent neu-
ral pathways and sending peripherally adequate instructions by efferent neural pathways. In these 
signals conduction an important role plays vagus nerve. Additionally central nervous system stays 
under influence of endocrine, paracrine and neuroendocrine signals taking part in these regulations, 
functioning directly onto the centre or on the afferent neural endings. 80–90% fibers of vagus nerve 
are afferent fibers, so their action is mainly afferent, but possible contribution of the efferent fibers 
cannot be excluded. Efferent stimulation induces motility and secretion in the intestinal tract. Afferent 
unmyelinated C-type fibres of the vagus nerve are more sensitive and easily electrically stimulated. 
Information from vagus nerve is transmitted to nucleus tractus solitarius, which has projections to 
nucleus arcuate of the medio-basal hypothalamus, involved in the control of feeding behavior.
It is suggested, that interaction onto the vagus nerve (stimulation or blocking) can be an alternative 
for other ways of obesity treatment. Through the manipulation of the vagus nerve activity the goal is 
achieved by influence on central nervous system regulating the energy homeostasis
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ROLE OF VAGUS NERVE IN WEIGHT CONTROL
Vagus nerve (VN), i.e. cranial nerve X, constitute a very important input to central 
nervous system (CNS) entering the peripheral information particularly from 
digestive tract. In 80–90% it is a sensory nerve [1, 2]. Vagus nerve is responsible 
for the transmission of the majority of the afferent signals responsible for satiety 
[3, 4]. Afferent pathway of gut-brain axis has a direction via afferent fibers of 
vagus nerves and spinal nerves (sympathetic) and is transducing information 
into the brain from stimulated receptors sensitive to various types/kinds of 
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stimulation: 1. mechanical — sensitive to changes in tension of gastrointestinal 
tract walls; 2. chemical — reacting to nutrients (food ingredients) in the gut 
lumen, and 3. neurohormonal stimuli such as gut hormones, neurotransmitters, 
neurostimulators, inflammatory mediators [5].
It has been demonstrated in rats that gastric distension increases vagus nerve 
activity [6]. Distension of either the stomach or the duodenum is one of the 
factors stimulating satiety [6].
Vagus nerve transmits centrally signals from mucosa stimulated by jejunal 
fatty acid infusions, what have been described in cats [7] and then in other 
animals [8, 9]. Vagotomy or capsaicin, component of chili peppers that selectively 
destroys vagal afferent fibers, eliminates decreasing appetite effect of fatty acids 
given into duodenum, while the effect of glucose given into duodenum is weaker, 
indicating that the control of glucose blood level remains under brain control.
Schwartz et al. demonstrated that combinations of gastric load and exogenous 
peptides excited gastric vagal mechanoreceptors to a greater degree than either 
stimulus alone [10]. These data indicate that individual gut vagal afferents 
possess distinct transduction mechanisms for the different classes of meal-related 
negative feedback signals, and can simultaneously integrate these signals to send 
a coherent message regarding meal size to the intake-regulation centre in the 
brain. Vagal afferent neurons, that synapse in the nucleus tractus solitarius (NTS) 
in the hindbrain, can integrate different information such as gastric distension, the 
luminal chemical environment, microbiota, and tissue health. That is why vagal 
afferent stimulation is involved in the control of food intake, gastric emptying, 
secretion from the stomach and pancreas [5].
VN also transmits different signals than these mentioned above. A variety of 
receptors for ligands with orexigenic (hunger, i.e. those stimulating appetite) and 
anorexigenic (satiety, i.e. those inhibiting appetite) properties have been identified 
on the vagal afferents.
Stimulation of serotonin receptor (5-HT3), cholecystokinin receptor (CCK1), 
vanilloid (capsaicin) receptor (VR1), tachykinin receptor (NK1) increases, but stimu-
lation by ghrelin, leptin, kappa-opioid and receptors for gamma-aminobutyric 
acid (GABAB) receptors decreases vagal activity [11].
Vagal afferent neurons are a primary target of CCK. Part of secreted CCK 
diffuses locally paracrinally and stimulates receptors CCK-A on vagal afferent 
neurons, ending in NTS [12–14]. Resistance to CCK occurs in obesity and is one 
of mechanism of food intake regulation changes in obesity. Vagotomy attenuates 
the response of the CCK on reduction of food intake. Ghrelin receptors are found 
on sensory fibers of the vagus nerve and can thus relay a signal to eat more 
to the CNS via peripheral nerves [15]. Vagus nerve circuits play a role in leptin 
secretion. Cigaina and Hirschberg reported decrease in leptin level significantly 
correlated with weight loss in patients with gastric pacing [16]. Wang and Liu 
did not find any changes in leptin level neither after vagus nerve dissection nor 
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after gastric bypass in rats [17]. However, leptin concentration was significantly 
diminished and correlated with weight loss in both studies. De Lartigue et 
al. demonstrated that diet-induced obesity leads to the development of leptin 
resistance in vagal afferent neurons and leptin signaling in vagal afferent neurons 
is required for appropriate cholecystokinin signaling and satiation, limiting meal 
size and duration [18, 19].
Y2R receptors for Peptide YY (PYY), an appetite suppressing hormone [20], are 
expressed on the VN [21]. Anorectic effect of PYY3-36 on food intake is abolished 
following subdiaphragmatic truncal vagotomy. PYY acts centrally inhibits gastric 
emptying and motility [22]. Pancreatic polypeptide (PP), another polypeptide from 
the “PP-fold” family of proteins, may act via vagus nerve, and the anorectic effect 
of it is abolished by vagotomy in rodents [23].
VN takes part in mediating signal via Glucagon-Like Peptide-1 (GLP-1) for 
food intake [20].
It has been reported that expression of receptors on vagal afferent neurons is 
modulated by diet, for example in nodose ganglia of mice fed a high fat diets 
decreased expression of CCK1 receptors has been reported [24]. It was also shown 
that both caloric restriction and high fat diet decrease mechanosensory vagal 
afferent signals in mice, and augment the inhibitory effect of ghrelin on vagal 
afferents, but different mechanisms mediate the short- and longer-term changes [25].
Vagus nerve also regulates guts’ absorption, its motility and energy utilization 
(feed efficiency) on the central level. Rats with electrical vagus nerve stimulation 
(VNS), on the cervical level, to gain their weight of 1 gram needed more kcal 
than control rats [26]. Mobilization of free fatty acids (FFA) from fat during VNS 
have been shown [26].
Left and right trunks of the VN have different distributions. Left (frontal) one 
has a hepatic branch of the vagus nerve, which is an important source of afferent 
input controlling both physiological and behavioral homeostasis. Liver detects 
changes in its energy and can transmit information regarding these changes into 
brain via VN. Evidences also exist, that liver is responsible for fatty acids and 
their metabolism fluctuations by sending signals to the brain with the help of 
VN [27]. Electrophysiological experiments showed most direct stimulation of the 
vagal sensory neurons. Niijima by extracellular recording showed that infusion of 
glucose and other nutrients, hormones and other factors stimulated VN [28, 29]. 
General concept, that VN plays an important integrative role in short-term 
regulation of food intake is still valid [30].
Electrical stimulation of the vagus nerve engages vagal afferents which mediate 
satiety signals from the gastrointestinal tracts. Experiments on animals have been 
started with the aim to explain whether VNS on the thoracic and abdominal level 
changes gut motility and absorption.
Vagus nerve stimulation (VNS) increases, in different brain regions, secretion 
of brain-derived neurotrophic factor (BDNF), which has been identified as a key 
component of pathways that controls body weight and energy homeostasis [26]. 
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Das proposed that VNS could be of significant benefit in metabolic syndrome, 
because VNS has been shown to suppress inflammation and reduces insulin 
resistance [31]. Efferent stimulation of vagus nerve inhibits inflammation and 
enhances cholinergic signaling within the inflammatory reflex, can suppress 
obesity-associated inflammation and its adverse implications [32].
Vagus nerve takes part in maintaining glucose homeostasis via its fibres 
components in liver, pancreatic  cells and hypothalamus. Species with resistance 
to insulin and metabolic syndrome developed subnormal vagal tone with high 
sympathetic one, which effect in low-grade systemic inflammation. The main vagal 
neurotransmitter, acetylcholine, inhibits proinflammatory cytokine release and thus 
suppresses inflammation. 
We previously showed that electrical vagus nerve stimulation decreases food 
intake and body weight in rats with short-term [33] and chronic vagal stimulation 
[34–36].
ROLE OF VAGUS NERVE IN THE REGULATION OF AMOUNT OF ADIPOSE TISSUE
Vagus nerves may influence the formation of visceral adipose tissue. Rats 
subdiaphragmatic total vagotomy and vagal deafferentiation with capsaicin have 
shown that both efferent and afferent vagal neural pathways are involved in the 
development of diet-induced obesity, and both efferent and afferent vagal neural 
pathways influence abdominal visceral adiposity (reduced in visceral abdominal 
fat), with consequent implications for the risk of the development of metabolic 
syndrome and cardiovascular disease [37].
We proved in rats with long-term vagal stimulation decrease of epididymal 
fat pad weight, reflecting the total body fat content [34–36]. In our experiment 
we observed significant serum leptin level decrease after VNS, correlating with 
decreased weigh gain and reduction in food consumption [38, 36].
Banni et al. recorded that exposure of rats to VNS for 4 weeks reduced feed 
conversion efficiency as well as body weight gain (by aprox. 25%) and the amount 
of mesenteric adipose tissue (by approx. 45%) in comparison with those in sham-
operated control animals [26].
The vagus nerve has a role in regulating weight by modulating visceral fat in 
humans. Miyato et al. described, measured in a computed tomography (CT) scans, 
decrease in visceral fat mass in 77 patients who had undergone gastrectomy due to 
early gastric cancer [39]. The reduction in visceral fat mass was significantly lower 
in vagus nerve-preserved than in vagus nerve-non-preserved cases. Reduction of 
the visceral fat, when the total fat tissue in these patients have been unchanged, 
is essential because this visceral fat is responsible for obesity results, more than 
mass of whole fat tissue of the body.
Kreier et al. reported that the intra-abdominal and subcutaneous fat pads in 
rats are innervated by separate parasympathetic neurons [40].
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From these anatomical and physiological relationships there is a rationale for 
nervus vagus manipulation in attempt for obesity treatment in humans.
ELECTRICAL VAGUS NERVE STIMULATION IN HUMANS
Obesity is a serious medical problem, more serious and dangerous because we 
lack effective ways of treatment. There are different possibilities for heavy obesity 
treatment. Bariatric surgery is the most effective form of treatment, but application 
of this therapy is limited by its side effects, and only the most seriously obese 
are, therefore, typically treated with bariatric surgery. Implantable devices that 
stimulate, block, or modulate vagal nerve activity are a new, potential treatment 
developed for weight loss.
Vagus nerve stimulation (VNS) is a wide general term relating to many 
different techniques of vagus nerve excitation. In experiments on animals vagus 
nerve was approachable and stimulated through the abdomen cavity, mainly 
subdiaphragmatically. In case of almost all experiments in humans VNS relates 
to stimulation of left cervical VN with the use of commercial device VNS Therapy 
System. 
WHY VAGUS NERVE STIMULATION IS USED IN OBESITY TREATMENT?
VNS seems to be logic solution because obesity is an energy imbalance regulated 
by CNS, and vagus nerve provides information from the periphery to the energy 
control center in the hypothalamus. VNS is safe and well-tolerated, safer than 
direct brain induction, and thus makes more attractive therapy option [41]. First 
treatment with VN stimulation has been applied in cats to stop epilepsy fit [42]. 
First VN stimulator in humans had been implanted in the year 1988 [43].
DATA FROM OBSERVATION MADE ON HUMANS WITH VAGUS NERVE STIMULATION
The role of vagus nerve part in body weight regulation can be traced since 1930 
in works of Dragstedt, who established vagotomy as the cure for peptic ulcer 
surgical treatment. This evolving method of peptic ulcer disease treatment brought 
more scientific experiments leading to include vagotomy as the obesity treatment 
as well. Increasing popularity of vagotomy made many new important clinical and 
experimental facts. Kral underlined that vagotomy on its own, which undoubtedly 
improved glucose homeostasis in operated patients, lead to a wide range of weight 
loss [44, 45]. Gastric pacing as the method of morbid obesity treatment was 
proposed by Cigaina [46].
Vagotomy for weight loss, however, never gained much popularity due to 
concerns for motility side effects as well as greater weight loss achieved by the 
evolving gastric bypass operation [47].
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First examinations with VNS in humans have not been carried on patients 
with obesity but with others illnesses. There is a clinical experience with VNS 
for epilepsy treatment. During VNS applied as an epilepsy treatment in some 
patients decrease in weight have been observed as a “side-effects” [48, 49]. After 
over 37 kg weight loss had been noticed in one patient with VNS Borneo at 
al. conducted a retrospective analysis of these data obtained from the group of 
27 patients and have noted weight loss in 17 of them. Weight loss in patients 
according to Burneo may be due to decreased appetite, resulting in changes in 
eating behavior, or to gastrointestinal side effects, such as dyspepsia, previously 
reported as a side effect of VNS [49]. Weight loss was observed as side effect in 
part of people treated with VNS during pharmacologically resistant epilepsy or 
depression treatment [50].
Kansagra et al. in first retrospective study on children with long-term VNS 
applied in epileptic children have not noticed any changes in body mass index 
(BMI) during VNS [51].
Koren and Holmes in retrospective analysis of body weight changes in 21 
patients with 2-year Cyberonics VNS Therapy System for epilepsy did not notice 
any body mass changes [52]. On the other hand Pardo at al. in 14 patients treated 
for drug resistant depression with VNS for over one year have reported significant, 
gradual weight loss despite the patients’ report of not dieting or exercising [53]. 
The weight loss was proportional to the initial BMI, that is, the more severe the 
obesity, the greater the weight loss. Patients were using NCP Model 101 device, 
Cyberonics Inc., USA for stimulation of left vagus nerve in neck area in its neck 
location. The right vagus is not used typically because of greater vagal side effects 
at the heart or pulmonary level.
Camilleri et al. in experiments with human with mean body mass index (BMI) 
39.3, sponsored by EnteroMedics Inc, using a laparoscopically implantable device 
to intermittent blockade of both subdiaphragmatic vagal nerves signaling with 
electrical pulses described effects VBLOC therapy (Vagal BLocking for Obesity 
Control) in obesity treatment [54, 55]. Implantable components were two 
flexible leads (including one electrode for each the anterior and posterior 
intra-abdominal vagal nerve trunks) that were connected to an implantable 
neuroregulator placed subcutaneously on the abdominal wall below the costal 
margin. Basing on his previous experimental work on pigs Camilleri set biphasic 
pulses at a frequency of 5000 Hz to block the neural impulses in the vagal 
trunks [56]. Both VN were stimulated for 90 seconds (first generation device) [54] 
or 120 seconds (second generator device) [55] periods with 5 minutes rest periods 
for 12 hours a day, from morning till evening. After six month of treatment body 
weight loss had been achieved, modest at 14.2% for first-generation device and 
22.7% decrease of excessive body weight for second generation device. Excess body 
weight was defined as total body weight less ideal body weight. It is not known 
how to explain obtained body mass reduction after implanting VBLOC whether as 
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blockade of efferent or afferent impulsation in vagus nerve [57]. Possible changes 
of hormonal milieu have not been examined [57]. Recently published randomized, 
double-blinded, multicenter, controlled big trial of intermittent vagal blockade 
in subjects with morbid obesity to verify the VBLOC study, comes from fifteen 
laboratory centers in USA and Australia [58]. Experiments were sponsored by 
EnteroMedics Inc, St. Paul, MN. Results from one year observation were carried on 
294 obese patients with BMI >41, with implanted devices, including 192 patients 
with implanted active/treated VBLOC and a group of 102 as non-treated control 
group. In summary, under the conditions of this EMPOWER study, authors were 
unable to demonstrate any difference in the treated and control groups in percent 
excess weight loss (EWL) [58]. 12-month percent EWL was 17 ± 2% for the treated 
and 16 ± 2 % for the control group.
VNS explains effect of acupunctural loosing weight in humans. Acupuncture 
stimulates auricular branch of vagus nerve. It is also responsible for the increase 
in serotonin (5-HT) level. Both changes lead to increased stomach smooth muscle 
tones, responsible for suppressing appetite [59].
WHAT SHOULD BE TAKEN INTO ACCOUNT DURING VAGUS NERVE STIMULATION?
WHAT PROBLEMS OCCUR DURING VAGUS NERVE STIMULATION?
Constant current stimulation or constant voltage stimulation?
Val-Laillet et al. in an interesting work with chronic VNS on both vagus 
nerves in minipigs used bilateral vagal electrodes connected to constant current 
stimulators (2 mA, 30 Hz, 500-ms pulse, ON 30 s, OFF 5 min), while most authors 
used constant voltage stimulation because the circuitry is simpler than constant 
current stimulation [60]. Unfortunately, in a voltage control scheme an increase 
in resistance anywhere in the electrical conduction path will cause an additional 
voltage drop, decreasing the current at the nerve level and potentially causing it 
to be insufficient for stimulation [61]. Because the level of neuronal membrane 
depolarization is related to the applied current, the voltage but not current control 
scheme results in a reduction of reproducibility between experiments and along 
the time course of the inflammatory response occurring at the nerve-electrode 
junction [61].
Stimulation of one or both vagus nerves?
VNS of both nerves is more efficient, but bilateral stimulation is more invasive 
[33]. Frontal (left) one has a liver branch.
Afferent or efferent stimulation?
Different scientists admit that they stimulate mainly afferent part (fibres) of 
vagus nerve [62]. Afferent unmyelinated C-type fibres of the vagus nerve are more 
sensitive and easily stimulated.
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One side VNS with vagotomy in opposite side?
Laskiewicz et al. showed that effects of both vagal nerves stimulation on final 
body weight and food intake was significantly more effective than only single nerve 
MC pacing in rats [33]. Sobocki et al. demonstrated that bilateral VNS is more 
effective than unilateral stimulation due to bilateral compensation [62].
Roslin and Kurian chose to investigate bilateral stimulation of the vagus nerve 
in dogs, because the right and left trunks have different distributions in the 
abdomen and the contribution of both could be essential [41].
Stimulation on what level?
On the abdominal level because on the neck level there are side effects 
described [49, 62].
Continuous or periodic stimulation?
Periodic better as chronic may lead to nerve damage [63].
IS VAGUS NERVE AN EFFICIENTLY STIMULATED INDEED?
WHAT ARE THE METHODS TO VERIFY THE VAGUS NERVE STIMULATION?
VNS may induce nerve alternation, as described in review by Cohen and 
Georgievskaya [64]. There is a possibility of vagus nerve damage or its regeneration 
after vagotomy. For obvious reasons morphological and functional verification 
of VNS effectiveness is not conducted on humans. Not many authors verify 
effectiveness of VNS in experiments on animals for example intracellular recording 
in NTS or by c-Fos/c-fos searching. Most authors abandon such verification and 
explain it somehow, but majority of them do not mention such problem. But one 
has to remember that effective stimulation and transmission of induction are 
vital. Val-Laillet histologically controlled VN at the location of the stimulating 
electrodes, showing only one stimulated nerve with signs of inflammation [60]. 
Some authors verified effectiveness of VNS declaring increased c-Fos expression 
immunoreactivity in neurons of nodose ganglion of vagus nerve after chronic left 
vagus nerve stimulation [65, 66].
It is also very important to remember that vagus nerve can be killed during 
prolonged or not adequate stimulation. One has to remember not to damage 
vagus nerve. Possible vagus nerve damage during electrostimulation is discussed 
in the elegant work of Cohen and Georgievskaya [64]. 
CONCLUSION
Vagus nerve plays an important role in regulation of nutrient homeostasis and 
body weight. Many already discovered mechanisms in which vagus nerves took 
part had been used in several ways of treatment, and those newly discovered 
and not yet known may become targets in obesity treatment.
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